#USA #Robbins Geller #San Diego #Class Action #Regeneron Pharmaceuticals

Overview

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is currently the subject of a class action lawsuit led by Robbins Geller Rudman & Dowd LLP. The lawsuit is specifically targeted at investors who experienced significant losses between August 1, 2025, and May 15, 2026. Those impacted by the alleged misleading information regarding Regeneron's clinical trials are encouraged to step forward and consider taking on the role of lead plaintiff in this case.

Background of the Case

The lawsuit, titled Cheatham v. Regeneron Pharmaceuticals, Inc., No. 26-cv-06026 (S.D.N.Y.), contends that Regeneron and some of its top executives violated the Securities Exchange Act of 1934. It claims that during the class period, the defendants made numerous false representations about the company's Phase III clinical trial for Fianlimab, while also failing to disclose important risks that could undermine the success of the study.

The allegations are serious and include claims that executives presented a misleadingly positive view of the trial's prospects while downplaying crucial setbacks. Specifically, the lawsuit posits that:

1. False Impressions of Reliability: Executives reinforced the belief that they had strong statistical backing that indicated success in the Phase III trial, masking issues that could jeopardize the study's outcomes.
2. Flawed Statistical Assumptions: The statistical methods employed were described in a way that misrepresented their validity.
3. Ineffectiveness Compared to Standard Treatments: The treatment being tested in the trial was allegedly not showing sufficient differentiation from existing therapies in terms of clinical efficacy.
4. Failure to Meet Study Goals: Key endpoints of the trial were ultimately not met, reflecting a deeper issue of authenticity in the company’s reporting.

Significant Price Drops

On April 29, 2026, during an earnings call, Regeneron's management revealed that significant changes had been made to the Phase III trial, which negatively impacted its core analysis metrics. Following this disclosure, Regeneron's stock fell over 6%. Later, on May 15, 2026, a press release claimed that the trial did not achieve its primary endpoints, leading to a steep drop of nearly 10% in stock value after market closure. These drastic movements reflect the market's dissatisfaction with the company's announcements and highlight the legal implications of such significant losses.

Role of Lead Plaintiff

Under the Private Securities Litigation Reform Act of 1995, any individual who purchased Regeneron common stock during the specified period is entitled to seek the position of lead plaintiff in this case. The lead plaintiff is expected to have the most substantial financial interest in the case and will represent the collective interests of all class members. Additionally, they will have the ability to select a law firm to guide the proceedings.

Being a lead plaintiff is advantageous as it gives the investor a prominent role in shaping the course of the lawsuit; however, it is important to note that recovery from the lawsuit is not contingent on this status.

About Robbins Geller Rudman & Dowd LLP

Robbins Geller Rudman & Dowd LLP is a premier law firm specializing in representing investors in securities fraud cases. The firm has a notable track record and is recognized for recovering over $916 million for clients in the past year alone. They have repeatedly achieved top rankings in the field and are one of the largest plaintiffs' firms globally, having recovered approximately $8.4 billion for investors over the last five years.

Individuals seeking more information about the Regeneron class action lawsuit or those interested in pursuing the role of lead plaintiff are encouraged to visit the Robbins Geller website or contact their attorneys for further assistance. Early action is encouraged as the deadline to file for the lead plaintiff position expires on September 14, 2026.